Annovis BioAdvance News Portfolio News

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

By WebmasterAugust 24, 2022November 1st, 2024No Comments

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

Previous PostAnnovis Bio Appoints Henry Hagopian III as Chief Financial Officer
Next PostImmunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer